Balyasny Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,917,501
| Closed | -$77.1M | – | 2982 |
|
|
2026
Q1 | $77.1M | Buy |
1,917,501
+1,852,368
| +2,844% | +$39.9M | 0.1% | 226 |
|
|
2025
Q4 | $1.64M | Buy |
+65,133
| New | +$1.53M | ﹤0.01% | 1967 |
|
|
2025
Q2 | – | Sell |
-324,487
| Closed | -$7.1M | – | 2783 |
|
|
2025
Q1 | $7.1M | Sell |
324,487
-419,707
| -56% | -$11.6M | 0.01% | 1096 |
|
|
2024
Q4 | $23.7M | Buy |
+744,194
| New | +$22.4M | 0.04% | 585 |
|
|
2024
Q3 | – | Sell |
-199,954
| Closed | -$7.41M | – | 2718 |
|
|
2024
Q2 | $7.67M | Sell |
199,954
-32,289
| -14% | -$1.46M | 0.01% | 996 |
|
|
2024
Q1 | $13.7M | Buy |
+232,243
| New | +$14.8M | 0.02% | 797 |
|
|
2023
Q3 | – | Sell |
-304,169
| Closed | -$27.7M | – | 2233 |
|
|
2023
Q2 | $27.7M | Sell |
304,169
-313,728
| -51% | -$27.1M | 0.06% | 422 |
|
|
2023
Q1 | $40.8M | Buy |
617,897
+361,556
| +141% | +$20.9M | 0.1% | 276 |
|
|
2022
Q4 | $13.3M | Buy |
256,341
+209,076
| +442% | +$11.1M | 0.04% | 621 |
|
|
2022
Q3 | $3.23M | Buy |
+47,265
| New | +$2.8M | 0.01% | 1241 |
|
|
2022
Q1 | – | Sell |
-128,514
| Closed | -$6.08M | – | 2454 |
|
|
2021
Q4 | $6.08M | Sell |
128,514
-54,633
| -30% | -$2.15M | 0.02% | 790 |
|
|
2021
Q3 | $6.04M | Buy |
+183,147
| New | +$10.3M | 0.03% | 757 |
|
|
2018
Q4 | – | Sell |
-60,000
| Closed | -$1.07M | – | 1372 |
|
|
2018
Q3 | $1.07M | Sell |
60,000
-5,428
| -8% | -$100K | ﹤0.01% | 1165 |
|
|
2018
Q2 | $1.44M | Buy |
+65,428
| New | +$1.5M | 0.01% | 1041 |
|
Other funds holding APLS
Balyasny Asset Management's APLS Position: Q2 2026 in Review
Balyasny Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,917,501 shares — an estimated $77.1M sold.
Balyasny Asset Management first reported a position in APLS in Q2 2018 and held it in 14 quarters. The position peaked at $77.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Balyasny Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Balyasny Asset Management sold 1,917,501 Apellis Pharmaceuticals shares in Q2 2026, an estimated $77.1M.
- Balyasny Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 14 quarters.
- Balyasny Asset Management's Apellis Pharmaceuticals position peaked at $77.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.